Abbott Laboratories manufactures and sells health care products worldwide. The company operates in four business segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Vascular Products. The company was founded in 1888 and is based in Abbott Park, Illinois.
ABT Price Forecast Based on DCF Valuation
DCF Fair Value Target:
Below please find a table outlining a discounted cash flow forecast for ABT, in which we model out valuation assuming a variety of terminal growth rates. To summarize, we found that Abbott Laboratories ranked in the 29th percentile in terms of potential gain offered. We should note, though, that all scenearios modelled for this stock suggest it is overvalued. The most interesting components of our discounted cash flow analysis for Abbott Laboratories ended up being:
As a business, ABT is generating more cash flow than 91.53% of positive cash flow stocks in the Healthcare.
The business' balance sheet suggests that 10% of the company's capital is sourced from debt; this is greater than merely 21.87% of the free cash flow producing stocks we're observing.
ABT's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 2%; for context, that number is higher than 40.63% of tickers in our DCF set.
Terminal Growth Rate in Free Cash Flow
Return Relative to Current Share Price
For other companies in the Healthcare that have a similar discounted cashflow valuation profile (and ensuing price forecasts) as ABT, try ESMC, HOLX, BHC, CNMD, and IONS.
NEW YORK , July 2, 2020 /CNW/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Co-Diagnostics, Inc. ("Co-Diagnostics" or the "Company")(CODX) and certain of its officers. The class action, filed in United States District Court for the District of Utah , Central Division, and indexed under 20-cv-00481, is on behalf of a class consisting of all persons and entities other than Defendants who purchased or otherwise acquired Co-Diagnostics securities between February 25, 2020 , and May 15, 2020 , both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and Rule 10b -...
The changing landscape in dividend growth investing is challenging. From an all-time high in late February, the S&P 500 lost more than 34% of its value due to uncertainties surrounding the impact of the coronavirus disease of 2019 (COVID-19) on the global economy. While the index has gained back most...
We at Insider Monkey have gone over 821 13F filings that hedge funds and prominent investors are required to file by the SEC The 13F filings show the funds' and investors' portfolio positions as of March 31st, near the height of the coronavirus market crash. We are almost done with the second quarter. Investors decided […]